Comment: JAVELIN-100 for metastatic urothelial cancer

HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve patients with advanced renal cell carcinoma

Updated results from KEYNOTE-426 for metastatic kidney cancer

PARP inhibitors in prostate cancer: Choices of tests and how to test?

Perioperative novel systemic immunotherapy-based approaches in urinary cancers

ASCO 2020: Updates in renal cancer

Highlights from ASCO 2020

PARP inhibitors in prostate cancer: Guidelines, who to test and the patient pathway

Association of BRCA alterations with response to PARP inhibitors in metastatic castration-resistant prostate cancer

LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progressing after docetaxel

Maintenance avelumab plus best supportive care (BSC) versus BSC alone after chemotherapy in advanced urothelial carcinoma

Prostate cancer patients receiving androgen-deprivation therapies shown to be at lower risk from COVID-19